Sachiyo Minegishi

Sachiyo Minegishi joined the AWFH board in August 2025. Sachiyo Minegishi is the Chief Operating Officer at Rectify Pharma, a venture backed startup developing a novel class of disease-modifying oral, small molecules specifically designed to rectify the dysfunction of membrane proteins. Prior to Rectify, Sachiyo served as Chief Financial Officer at Akouos, Inc., where she helped lead the acquisition of the company by Eli Lily. Over her career in biotechnology, Sachiyo has held leadership roles in a breadth of functions such as program leadership, commercial, and business development at bluebird bio, Aegerion Pharmaceuticals, Human Genome Sciences, Genzyme, and Amgen. Sachiyo began her career in investment banking at Merrill Lynch, with a focus on the execution of equity financing and mergers and acquisitions in the biotechnology industry.

Sachiyo earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania. Sachiyo also serves on the Board of Mural Oncology, a public biotechnology company.